Menu Close

Articles on Biogen

Displaying all articles

Alzheimer’s disease is characterized by progressive memory loss, spatial disorientation and many other cognitive and behavioural disorders that ultimately lead to a state of total dependence. (Shutterstock)

FDA approval of controversial Alzheimer’s drug could delay discovery of more promising treatments

The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
Do the benefits of approving a drug before confirming it works outweigh the potential costs? monkeybusinessimages/iStock via Getty Images Plus

The FDA’s big gamble on the new Alzheimer’s drug

The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
In most cases, scientists are still unsure of what causes Alzheimer’s disease. FGC / Shutterstock.com

No cure for Alzheimer’s disease in my lifetime

After the failure of multiple drug trials the outlook for an Alzheimer’s drug is bleak. This shouldn’t be a surprise. We don’t know the cause or even how to diagnose the disease.

Top contributors

More